SCIENCE LIBRARY · UNITED STATES
Original scientific explainers with study data, limitations and links to practical guides. Each study is interpreted in its own population and treatment context.
Start with the outcome you want to understand. A change in weight, a symptom score and a reduction in clinical events answer different questions.
Browse the chart and data collection →SCIENTIFIC ARTICLE
Semaglutide reduced major cardiovascular events in a defined secondary-prevention population. Understanding the endpoint, absolute difference, treatment discontinuation, and product boundaries shows where clinical evidence ends and service marketing begins.
SCIENTIFIC ARTICLE
Semaglutide improved important outcomes in a defined population with type 2 diabetes and chronic kidney disease. Understanding the trial’s eligibility rules, composite endpoint, and follow-up is essential before turning that evidence into a service claim.
SCIENTIFIC ARTICLE
SURMOUNT-4 established a strong continuation-versus-withdrawal effect. Newer dose-reduction research adds options to the scientific picture, but neither study validates a provider’s maintenance guarantee.
SCIENTIFIC ARTICLE
A year after semaglutide and structured lifestyle support ended, participants regained about two-thirds of their average weight loss. The study supports planning for maintenance, not universal predictions or subscription guarantees.
SCIENTIFIC ARTICLE
A randomized comparison found greater average weight loss with injectable tirzepatide than injectable semaglutide at 72 weeks. The result supports a specific clinical claim, not a provider ranking, safety guarantee, or promise about compounded products.
SCIENTIFIC ARTICLE
Two randomized trials found substantial reductions in breathing interruptions with tirzepatide. Understanding the hourly measurements, PAP populations, and remaining uncertainty is essential before turning those results into a treatment promise.
SCIENTIFIC ARTICLE
Semaglutide improved symptoms, physical limitations, weight, and walking performance in a 529-person trial. Those findings support a specific clinical claim, not a guarantee of survival, an equivalent compounded product, or a provider’s results.
SCIENTIFIC ARTICLE
Tirzepatide reduced a combined heart-failure outcome in SUMMIT, but that result is not proof of longer survival, a guarantee for an individual, or evidence for every product sold under the same drug name.
SCIENTIFIC ARTICLE
Three years of tirzepatide sharply reduced progression to type 2 diabetes among trial participants with obesity and prediabetes. The evidence is substantial, but it does not establish a cure, permanent protection, or a guarantee from a treatment service.
SCIENTIFIC ARTICLE
SURMOUNT-1 scans showed substantially more fat loss than lean-tissue loss. Understanding the denominators, the small paired-scan sample, and a corrected figure is essential before turning those findings into service promises.